B-cell Non Hodgkin Lymphoma Clinical Trial
Official title:
Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL
To study the safety and effectiveness of cord blood-derived CAR-NK cells targeting CD19 in patients with B-cell non-Hodgkin's lymphoma
This is an open, single-arm, single-dose, dose-escalation clinical trial designed to evaluate the safety and the preliminary efficacy of CB CAR-NK019 cells. 9-18 patients are planned to be enrolled in the dose-escalation trial (2×10^6 cells/kg ,3×10^6 cells/kg, 4×10^6 cells/kg) . The primary endpoints are DLT, MTD, and the second endpionts are the overall response rates (CR and PR), overall survival, and progression-free survival. Based on the results in the dose-escalation trial, the recommended dose will be determined. Another 30 patients will be enrolled to estimate the safety and efficacy of CB CAR-NK019 under the best dose. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03114865 -
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04836195 -
Phase I Trial of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma
|
Phase 1 | |
| Active, not recruiting |
NCT04088890 -
Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
|
Phase 1 | |
| Recruiting |
NCT04191941 -
Treatment of Hematological Malignancy With Novel CAR-T Cells.
|
Early Phase 1 | |
| Active, not recruiting |
NCT04148430 -
A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy
|
Phase 2 | |
| Recruiting |
NCT05702853 -
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05991388 -
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04887012 -
Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL
|
Phase 1 | |
| Completed |
NCT04030195 -
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04594642 -
A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
|
Phase 1 | |
| Recruiting |
NCT05338931 -
Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05164770 -
Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma
|
Phase 3 | |
| Completed |
NCT05260203 -
MargheRITA (Remote Intelligence for Therapeutic Adherence)
|
N/A | |
| Active, not recruiting |
NCT05094206 -
CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies
|
Phase 1 | |
| Not yet recruiting |
NCT04412174 -
A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL
|
Early Phase 1 | |
| Completed |
NCT04748185 -
Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies
|
||
| Active, not recruiting |
NCT03283137 -
Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL
|
Phase 1 | |
| Completed |
NCT02910063 -
Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05744037 -
Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells
|
Phase 2 | |
| Active, not recruiting |
NCT03870945 -
Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1)
|
Phase 1/Phase 2 |